-+ 0.00%
-+ 0.00%
-+ 0.00%
Huadong Pharmaceutical announced that the company's wholly-owned subsidiary, the company's wholly-owned subsidiary, was included in the drug section negotiated during the new national medical insurance catalogue agreement; the cooperative product proline gaglinet tablets completed medical insurance renewal, and payment standards and scope remained unchanged; tacrolimus granules were adjusted to regular medical insurance catalogue management, and the scope of payment did not change; the cooperative product Zevokiolensis injection continues to be included in the new commercial insurance innovative drug catalogue. The new drug catalogue will be implemented on January 1, 2027. The above matters have no significant impact on the company's recent performance, and it is expected to help promote the product market in the future.
Share
Listen to the news
Huadong Pharmaceutical announced that the company's wholly-owned subsidiary, the company's wholly-owned subsidiary, was included in the drug section negotiated during the new national medical insurance catalogue agreement; the cooperative product proline gaglinet tablets completed medical insurance renewal, and payment standards and scope remained unchanged; tacrolimus granules were adjusted to regular medical insurance catalogue management, and the scope of payment did not change; the cooperative product Zevokiolensis injection continues to be included in the new commercial insurance innovative drug catalogue. The new drug catalogue will be implemented on January 1, 2027. The above matters have no significant impact on the company's recent performance, and it is expected to help promote the product market in the future.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending